[{"address1": "2222 Ponce de Leon Blvd.", "address2": "Floor 3", "city": "Coral Gables", "state": "FL", "zip": "33134", "country": "United States", "phone": "786 629 1376", "website": "https://www.relmada.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sergio  Traversa M.B.A., Pharm.D.", "age": 64, "title": "CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1800723, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Maged S. Shenouda M.B.A., R.Ph.", "age": 60, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 993750, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul E. Kelly M.B.A.", "age": 67, "title": "COO & Director", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 872780, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles S. Ence CPA, M.B.A.", "age": 59, "title": "Chief Accounting & Compliance Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 983039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gina  DiGuglielmo", "title": "VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew  Cutler", "title": "Senior Clinical Development Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard M. Mangano Ph.D.", "age": 74, "title": "Consultant", "yearBorn": 1950, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 4, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.615, "open": 0.5904, "dayLow": 0.5804, "dayHigh": 0.6639, "regularMarketPreviousClose": 0.615, "regularMarketOpen": 0.5904, "regularMarketDayLow": 0.5804, "regularMarketDayHigh": 0.6639, "payoutRatio": 0.0, "beta": 0.181, "forwardPE": -0.31810945, "volume": 740041, "regularMarketVolume": 740041, "averageVolume": 1760300, "averageVolume10days": 1047910, "averageDailyVolume10Day": 1047910, "bid": 0.6206, "ask": 0.6463, "bidSize": 9, "askSize": 9, "marketCap": 21222710, "fiftyTwoWeekLow": 0.24, "fiftyTwoWeekHigh": 4.47, "fiftyDayAverage": 0.3707, "twoHundredDayAverage": 1.505265, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -5838309, "profitMargins": 0.0, "floatShares": 25500791, "sharesOutstanding": 33191600, "sharesShort": 2034623, "sharesShortPriorMonth": 1622417, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.061300002, "heldPercentInsiders": 0.17025, "heldPercentInstitutions": 0.33472002, "shortRatio": 0.53, "shortPercentOfFloat": 0.0627, "impliedSharesOutstanding": 33191600, "bookValue": 0.744, "priceToBook": 0.8594086, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -75710696, "trailingEps": -2.51, "forwardEps": -2.01, "lastSplitFactor": "1:4", "lastSplitDate": 1569801600, "52WeekChange": -0.7833898, "SandP52WeekChange": 0.09362543, "quoteType": "EQUITY", "currentPrice": 0.6394, "targetHighPrice": 1.0, "targetLowPrice": 0.6, "targetMeanPrice": 0.86667, "targetMedianPrice": 1.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 27061032, "totalCashPerShare": 0.815, "totalDebt": 0, "quickRatio": 5.173, "currentRatio": 5.287, "returnOnAssets": -0.88236, "returnOnEquity": -1.60257, "freeCashflow": -30054128, "operatingCashflow": -56786084, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RLMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Relmada Therapeutics, Inc.", "longName": "Relmada Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1748037251, "regularMarketTime": 1748030401, "exchange": "NMS", "messageBoardId": "finmb_9070579", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1403271000000, "fiftyTwoWeekHighChangePercent": -0.8569575, "fiftyTwoWeekChangePercent": -78.33898, "dividendDate": 1569801600, "earningsTimestamp": 1747080060, "earningsTimestampStart": 1754391540, "earningsTimestampEnd": 1754913600, "earningsCallTimestampStart": 1747081800, "earningsCallTimestampEnd": 1747081800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.51, "epsForward": -2.01, "epsCurrentYear": -1.15, "priceEpsCurrentYear": -0.556, "fiftyDayAverageChange": 0.2687, "fiftyDayAverageChangePercent": 0.7248449, "twoHundredDayAverageChange": -0.865865, "twoHundredDayAverageChangePercent": -0.5752243, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "postMarketChangePercent": -1.48577, "postMarketPrice": 0.6299, "postMarketChange": -0.00950003, "regularMarketChange": 0.024399996, "regularMarketDayRange": "0.5804 - 0.6639", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1760300, "fiftyTwoWeekLowChange": 0.3994, "fiftyTwoWeekLowChangePercent": 1.6641667, "fiftyTwoWeekRange": "0.24 - 4.47", "fiftyTwoWeekHighChange": -3.8305998, "regularMarketChangePercent": 3.9674788, "regularMarketPrice": 0.6394, "displayName": "Relmada Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-24"}]